Legal Status Both 5-Amino-1MQ and AOD-9604 are not approved by the U.S
When two peptides work synergistically, each can often be used at lower doses than would be required if used independently
For hypermobile EDS and related hypermobility spectrum disorders, where chronic joint pain, instability, and repeated injuries dominate the clinical picture, prolotherapy and PRP have shown particular benefit
Always consult a qualified healthcare provider before considering or discussing peptide therapy
Archived from the original on January 12, 2018
Company Details Sapra Healthcare is a dynamic and innovative multispecialty company committed to enhancing human health and well-being through a diverse portfolio of pharmaceutical products, medical devices, and nutraceuticals